StockIQpro
NASDAQ:PDSB

PDS Biotechnology Corp

Track all markets on TradingView
Track all markets on TradingView

PDS Biotechnology Corp reported net income of −$34.5M in fiscal 2025. Free cash flow was −$27.8M, and the diluted share count rose 27.2%.Summary generated from PDS Biotechnology Corp's SEC filings. Latest annual report filed Mar 30, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−244.2%
Debt / equityn/a
Free cash flow−$27.8M
FCF marginn/a
Share count change+27.2%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−21−42−43−36−32
Net income−17−41−43−38−34
Free cash flown/an/a−34−35−28

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations